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TO THE EDITOR
Rosacea is a chronic facial skin disease,
with neurovascular dysregulation and
neurogenic inflammation as presumed
pathogenic key factors (Steinhoff
et al., 2011). Spironolactone is recom-
mended as an off-label treatment for
rosacea, despite scarce evidence of
efficacy (Powell, 2005; Rathnayake and
Sinclair, 2010) (http://www.cks.nhs.uk/
rosacea/management/scenario_rosacea#
335449004, accessed 04 March 2013).
Using the UK-based General Practice
Research Database (GPRD) (Khan
et al., 2010), we conducted a large
population-based case–control analysis,
including patients with a first-time diag-
nosis of rosacea (index date) between
January 1995 and September 2009.
We excluded patients with recorded
alcoholism, cancer, or HIV, and patients
with o3 years of recorded active
history before the index date. Patients
with diagnosed rhinophyma or ocular
rosacea only were excluded. We ran-
domly matched one control to each
case on age, sex, general practice,
calendar time, and number of previous
years of recorded history in the data-
base, and applied the same exclusion
criteria to controls as to cases. The study
protocol was approved by the Indepen-
dent Scientific Advisory Committee
(ISAC) for MHRA database research.
We assessed the use of diuretics (includ-
ing combined products) before the
index date, classified according to the
WHO ATC index (http://www.whocc.
no/atc_ddd_index/?code=C03, accessed
27 December 2012) into low-ceiling
diuretics, high-ceiling diuretics, and potas-
sium sparing agents (spironolactone vs.
amiloride/triamterene). We stratified
drug use by timing (last prescriptionpor
4180 days before the index date) and
duration of use (number of prescriptions
before the index date). To account for
confounding by indication, we per-
formed two sensitivity analyses; in the
first model, we classified spironolactone
users into those with or without a
previous diagnosis of acne, seborrhea,
hirsutism, or androgenic alopecia
(dermatological off-label indications for
spironolactone), overall and stratified by
exposure duration (stratified by gender
as Supplementary Table S1 online;
Rathnayake and Sinclair, 2010). In the
second model, we classified current
spironolactone users into patients with
or without concomitantly (p180 days)
prescribed cardiovascular drugs, such
as ACE inhibitors, angiotensin receptor
blockers, beta-blockers, calcium chan-
nel blockers, thiazide- or loop diuretics,
and nitrates (i.e., likely cardiovascular
indication vs. likely dermatological
indication). We conducted multivariate
conditional logistic regression analyses
using SAS statistical software (version
9.3, SAS Institute, Cary, NC), and
calculated odd ratios (ORs) with 95%
confidence intervals (CIs). We adjusted
all ORs for smoking (non, current,
ex, unknown), alcohol consumption (0,
1-4, 5-9, 10-14, 15-24, or 25þ units
per week, or unknown), and body mass
index (o18.5, 18.5–24.9, 25.0–29.9,
30þ kg m2, or unknown). Each
diuretic drug class was adjusted
for other diuretics and for drug classes
contained in combined products, if
applicable. Because other potential con-
founders, i.e., cardiovascular drugs (ACE
inhibitors, angiotensin receptor bloc-
kers, calcium channel blockers, beta-
blockers, and statins), anti-androgenic
drugs, hormone replacement therapy,
or cardiovascular comorbidities (hyper-
tension, myocardial infarction, heart
failure, ischemic stroke/transient ische-
mic attack, ischemic heart disease,
diabetes mellitus, and hyperlipidemia)
did not alter the relative risk estimates
for the association between the use of
diuretics or spironolactone and rosacea
by X10%, we did not include them in
the final model.
The study population’s demographics
and methodology including limitations
have been described in detail elsewhere
(Spoendlin et al., 2012). Among 53,927
rosacea cases and the same number of
controls, 8,372 (15.5%) cases and 7,926
(14.7%) controls had X1 recorded
prescription for a diuretic drug before
the index date (Table 1). While high-
ceiling diuretics, low-ceiling diuretics,
and amiloride/triamterene yielded ORs
around 1.0 across all strata, spirono-
lactone use (281 cases, 327 controls)
revealed an overall adjusted OR of 0.83
(95% CI 0.70–0.98), which dropped to
an OR of 0.47 (95% CI 0.35–0.63) in
current users at the index date. At an
a-level of 0.05 and a current spirono-
lactone exposure prevalence of 0.5%
among cases, the statistical power
to detect an OR of 0.5 is 99%.
We observed an OR of 0.39 (95% CI
0.27–0.54) in current spironolactone
users without a previous diagnosis for
an androgenic skin disease (Table 2).
This finding was consistent in men
and women (Supplementary Table S1
online). We further observed an OR
of 0.39 (95% CI 0.24–0.64) in current
long-term spironolactone users with
concomitant cardiovascular medication,
whereas patients without such medica-
tion revealed an overall OR of 0.68
(95% CI 0.35–1.32).
While the decreased relative risks
suggest that rosacea develops at a
substantially decreased rate during spi-
ronolactone exposure, the mechanism
remains unclear. As no other class of
diuretics affected the risk estimate, a
diuretic drug effect is an unlikely cause
for the observed effect. Spironolac-
tone is an aldosterone receptor antago-
nist with anti-androgenic properties
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(inhibition of androgen production and
antagonism at the androgen receptor).
Oral spironolactone has been proposed
as rosacea treatment, based on benefi-
cial results of a small uncontrolled
clinical trial in Japanese men. The
authors hypothesized an inhibition of
skin-specific cytochromes underlying
the observed effect (Aizawa and
Table 1. Distribution of diuretic exposure stratified by timing and duration of drug use in rosacea cases and controls
in the United Kingdom
Rosacea cases
(n¼ 53,927) (%)
Rosacea-free controls
(n¼ 53,927) (%) OR crude 95% CI OR adj.1 95% CI
No high-ceiling diuretics 50,817 (94.2) 50,990 (94.6) (1.0) (ref.) (1.0) (ref.)
Use of high-ceiling diuretics 3,110 (5.8) 2,937 (5.5) 1.07 (1.01–1.13) 1.06 (0.99 1.13)
Duration (no. of prescriptions)
1–19 2,184 (4.1) 1,971 (3.7) 1.12 (1.051.19) 1.09 (1.02 1.17)
20–39 391 (0.7) 432 (0.8) 0.91 (0.791.05) 0.89 (0.77 1.03)
40þ 535 (1.0) 534 (1.0) 1.02 (0.901.15) 0.98 (0.85 1.11)
Timing (180 days)
Current 1,331 (2.5) 1,444 (2.7) 0.93 (0.861.01) 0.88 (0.81 0.96)
Past 1,779 (3.3) 1,493 (2.8) 1.20 (1.121.29) 1.18 (1.09 1.27)
No low-ceiling diuretics 47,428 (88.0) 47,811 (88.7) (1.0) (ref.) (1.0) (ref.)
Use of low-ceiling diuretics 6,499 (12.1) 6,116 (11.3) 1.09 (1.041.13) 1.07 (1.02 1.12)
Duration (no. of prescriptions)
1–19 3,877 (7.2) 3,417 (6.3) 1.15 (1.101.21) 1.13 (1.07 1.19)
20–39 1,241 (2.3) 1233 (2.3) 1.03 (0.951.11) 1.00 (0.92 1.09)
40þ 1,381 (2.6) 1466 (2.7) 0.96 (0.881.04) 0.93 (0.85 1.01)
Timing (180 days)
Current 3,225 (6.0) 3,255 (6.0) 1.01 (0.96–1.07) 0.99 (0.94–1.05)
Past 3,274 (6.1) 2,861 (5.3) 1.17 (1.11–1.23) 1.15 (1.09–1.22)
No amiloride/triamterene 52,128 (96.7) 52,278 (96.9) (1.0) (ref.) (1.0) (ref.)
Use of amiloride/triamterene 1,799 (3.3) 1,649 (3.1) 1.11 (1.03–1.19) 1.07 (0.99–1.16)
Duration (no. of prescriptions)
1–19 1,162 (2.2) 1,038 (1.9) 1.13 (1.04–1.23) 1.09 (0.99–1.20)
20–39 259 (0.5) 269 (0.5) 0.98 (0.82–1.17) 0.95 (0.79–1.14)
40þ 378 (0.7) 342 (0.6) 1.12 (0.96–1.30) 1.08 (0.93–1.27)
Timing (180 days)
Current 552 (1.0) 529 (1.0) 1.06 (0.94–1.20) 1.01 (0.88–1.15)
Past 1,247 (2.3) 1,120 (2.1) 1.13 (1.04–1.23) 1.10 (1.00–1.20)
No spironolactone 53,646 (99.5) 53,600 (99.4) (1.0) (ref.) (1.0) (ref.)
Use of spironolactone 281 (0.5) 327 (0.6) 0.86 (0.73–1.01) 0.83 (0.70–0.98)
Duration (no. of prescriptions)
1–19 232 (0.4) 244 (0.5) 0.95 (0.79–1.13) 0.93 (0.77–1.12)
20–39 30 (0.1) 51 (0.1) 0.59 (0.37–0.92) 0.54 (0.34–0.85)
40þ 19 (0.0) 32 (0.1) 0.59 (0.34–1.04) 0.57 (0.32–1.01)
Timing (180 days)
Current 67 (0.1) 134 (0.3) 0.49 (0.37–0.66) 0.47 (0.35–0.63)
Past 214 (0.4) 193 (0.4) 1.11 (0.91–1.36) 1.09 (0.89–1.33)
Abbreviations: adj., adjusted; CI, confidence interval; OR, odds ratio.
1Adjusted for smoking, body mass index, alcohol consumption, complementary diuretic drug classes, drug classes contained in combined products.
Percentages are rounded to the nearest tenth digit.
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Niimura, 1992). Androgenic sebaceous
stimulation has been discussed
controversially with regard to rosacea
(Pye et al., 1976; Erkek et al., 2004;
Powell, 2005). Besides sebaceous
activities, the androgen receptor has
been linked to delayed wound repair,
enhanced epidermal hyperplasia and
collagen formation, proinflammatory
properties, and an inhibitory effect on
immune functions (Markova et al., 2004;
Lai et al., 2012). Furthermore, activation
of the aldosterone receptor (expressed
in human skin) promotes inflammation,
which is blocked by spironolactone
(Chantong et al., 2012; Odermatt and
Kratschmar, 2012). Evidence also emer-
ged for a nonreceptor-mediated vaso-
dilatory androgen effect (Perusquia and
Stallone, 2010). Sensitivity analyses
revealed decreasing ORs with increasing
confidence of diagnostic accuracy and
of unbiased indication (i.e., in patients
with a likely cardiovascular context and
in patients without certain dermatological
co-diagnoses). However, although we
accounted for such bias, some residual
confounding by indication or chance
cannot be ruled out. To our knowledge,
this is the largest study on the association
between spironolactone and rosacea.
We are not aware of previous studies
reporting a spironolactone effect on
rosacea in women or a potential asso-
ciation between other diuretics and
rosacea. As a certain efficacy in treating
dermatological diseases with topically
applied spironolactone has been shown,
local spironolactone application might be
a promising approach for the treatment of
rosacea (Messina et al., 1990; Yamamoto
and Ito, 1996; Rathnayake and Sinclair,
2010).
CONFLICT OF INTEREST
JJ Voegel is an employee at Galderma. The other
authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by an unconditional grant
by Galderma, France. This study was conducted in
Basel, Switzerland.
Julia Spoendlin1,2, Johannes J. Voegel3,
Susan S. Jick4 and
Christoph R. Meier1,2,4
1Basel Pharmacoepidemiology Unit, Division of
Clinical Pharmacy and Epidemiology,
Department of Pharmaceutical Sciences,
University of Basel, Basel, Switzerland;
2Hospital Pharmacy, University Hospital Basel,
Basel, Switzerland; 3Galderma Research and
Development, Sophia Antipolis, France and
4Boston Collaborative Drug Surveillance
Program, Boston University, Lexington,
Massachusetts, USA
E-mail: christoph.meier@usb.ch
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Aizawa H, Niimura M (1992) Oral spironolactone
therapy in male patients with rosacea.
J Dermatol 19:293–7
Chantong B, Kratschmar DV, Nashev LG et al.
(2012) Mineralocorticoid and glucocorticoid
receptors differentially regulate NF-kappaB
activity and pro-inflammatory cytokine pro-
duction in murine BV-2 microglial cells.
J Neuroinflammation 9:260
Erkek E, Bozdogan O, Kocak M et al. (2004)
Androgen receptor status in lesional and
normal skin of patients with rosacea. J Eur
Acad Dermatol Venereol 18:736–7
Khan NF, Harrison SE, Rose PW (2010) Validity of
diagnostic coding within the General Practice
Research Database: a systematic review. Br J
Gen Pract 60:e128–36
Lai JJ, Chang P, Lai KP et al. (2012) The role of
androgen and androgen receptor in skin-related
disorders. Arch Dermatol Res 304:499–510
Markova MS, Zeskand J, McEntee B et al. (2004) A
role for the androgen receptor in collagen
content of the skin. J Invest Dermatol
123:1052–6
Table 2. Use of spironolactone in rosacea cases and controls, after controlling for confounding by indication
Rosacea cases
(n¼ 53,927) (%)
Rosacea-free controls
(n¼ 53,927) (%) OR crude (95% CI) OR adj.1 (95% CI)
No spironolactone 53,646 (99.5) 53,600 (99.4) 1.00 (ref.) 1.00 (ref.)
Spironolactone with A/S/H/A 91 (0.2) 32 (0.1) 2.82 (1.89–4.22) 2.91 (1.94–4.37)
Spironolactone without A/S/H/A 190 (0.4) 295 (0.6) 0.64 (0.53–0.77) 0.65 (0.54–0.78)
Duration (no. of prescriptions)
1–19 153 (0.3) 217 (0.4) 0.70 (0.57–0.86) 0.72 (0.59–0.90)
20þ 37 (0.1) 78 (0.1) 0.47 (0.32–0.70) 0.46 (0.31–0.68)
Timing (180 days)
Current 47 (0.1) 123 (0.2) 0.38 (0.27–0.53) 0.39 (0.27–0.54)
Past 143 (0.3) 172 (0.3) 0.83 (0.66–1.04) 0.85 (0.67–1.07)
Current spironolactone with
cardiovascular co-medication
52 (0.1) 112 (0.2) 0.46 (0.33–0.64) 0.46 (0.33–0.65)
Duration (no. of prescriptions)
1–19 30 (0.1) 57 (0.1) 0.51 (0.33–0.80) 0.54 (0.34–0.85)
20þ 22 (0.0) 55 (0.1) 0.40 (0.24–0.65) 0.39 (0.24–0.64)
Current spironolactone without
cardiovascular co-medication
15 (0.0) 22 (0.0) 0.68 (0.35–1.31) 0.68 (0.35–1.32)
Abbreviations: adj., adjusted; A/S/H/A, acne/seborrhea/hirsutism/alopecia; CI, confidence interval; OR, odds ratio.
1Adjusted for smoking, body mass index, alcohol consumption, complementary diuretic drug classes, drug classes contained in combined products.
Percentages are rounded to the nearest tenth digit.
J Spoendlin et al.
Spironolactone and Rosacea
2482 Journal of Investigative Dermatology (2013), Volume 133
Messina M, Manieri C, Musso MC et al. (1990) Oral
and topical spironolactone therapies in skin
androgenization. Panminerva medica 32:49–55
Odermatt A, Kratschmar DV (2012) Tissue-specific
modulation of mineralocorticoid receptor func-
tion by 11beta-hydroxysteroid dehydrogenases:
an overview. Mol Cell Endocrinol 350:168–86
Perusquia M, Stallone JN (2010) Do androgens
play a beneficial role in the regulation of
vascular tone? Nongenomic vascular effects
of testosterone metabolites. Am J Physiol
Heart Circul Physiol 298:H1301–7
Powell FC (2005) Clinical practice. Rosacea.
N Engl J Med 352:793–803
Pye RJ, Meyrick G, Burton JL (1976) Skin surface
lipid composition in rosacea. Br J Dermatol
94:161–4
Rathnayake D, Sinclair R (2010) Use of spirono-
lactone in dermatology. Skinmed 8:328–32
Spoendlin J, Voegel JJ, Jick SS et al. (2012) A study
on the epidemiology of rosacea in the U.K.
Br J Dermatol 167:598–605
Steinhoff M, Buddenkotte J, Aubert J et al. (2011)
Clinical, cellular, and molecular aspects in
the pathophysiology of rosacea. J Investig
Dermatol Symp Proc 15:2–11
Yamamoto A, Ito M (1996) Topical spironolactone
reduces sebum secretion rates in young
adults. J Dermatol 23:243–6
Novel and Recurrent AAGABMutations: Clinical Variability
and Molecular Consequences
Journal of Investigative Dermatology (2013) 133, 2483–2486; doi:10.1038/jid.2013.171; published online 16 May 2013
TO THE EDITOR
Hereditary palmoplantar keratoderma
(PPK) refers to a group of disorders
characterized by excessive epidermal
thickening of the palms and soles,
caused by mutations in several genes
(Kelsell and Stevens, 1999; Kimyai-
Asadi et al., 2002; Itin and Fistarol,
2005; Braun-Falco, 2009). Punctate PPK
is a relatively common entity (Itin and
Fistarol, 2005) characterized by numer-
ous punctate hyperkeratotic papules on
the palms and soles, occurring during
childhood or early adulthood (Buschke
and Fischer, 1910; Kimyai-Asadi et al.,
2002; Emmert et al., 2003a, b). Recently,
two back-to-back studies employed
linkage analyzes and exome sequenc-
ing to identify the gene responsible for
the punctate PPK linked to chromosome
15q22. In three large families, two distinct
heterozygous nonsense mutations in the
a- and g-adaptin binding gene (AAGAB),
coding for the AAGAB protein p34 were
disclosed (Giehl et al., 2012). Eight dif-
ferent nonsense, frame-shift, or splice-
site AAGAB mutations were identified in
18 further families (Pohler et al., 2012).
Here we report the clinical and mole-
cular characteristics of four patients
from three unrelated families with punc-
tate PPK, and analyze the consequences
of a heterozygous AAGAB splice-site
mutation in primary keratinocytes.
The 75-year-old patient 1 had par-
tially coalesced hyperkeratotic papules
on the palms and soles, more pro-
nounced on points of mechanical
pressure (Figure 1a). All nails were
thickened and dystrophic. Onset of the
skin lesions was in childhood and the
patient’s father, brother, and sons were
also affected. Hematoxylin and eosin
staining of a skin sample from the sole
revealed orthohyperkeratosis, areas of
columnar parakeratosis with reduced
granular layer, and perivascular, mostly
lymphocytic, infiltrates in the upper
dermis (not shown). The 48-year-old
patient 2 had punctate PPK, more pro-
minent on the soles since the age of 30
years (Figure 1b). The 50-year-old
patient 3 (Figure 1c) and the 46-year-
old patient 4, who are sisters, had first
symptoms in adolescence. Interestingly,
patient 4 reported that the lesions had
vanished during chemotherapy for breast
cancer, and reappeared gradually after
completion of the therapy (Figure 1d).
For mutation analysis, EDTA blood
was obtained from the patients follow-
ing written informed consent in adher-
ence to the Declaration of Helsinki
Principles and after approval by the
ethics committee of the University of
Freiburg. The primers for amplification
of AAGAB were designed with Primer 3
(http://frodo.wi.mit.edu/; Supplementary
Table S1 online). In all patients, hetero-
zygous AAGAB mutations were found:
c.870þ1G4A at the donor splice-site
of exon 9 in patient 1, c.21T4A, p.C7X
in patient 2 (Supplementary Figure S1
online), and c.481C4T, p.R161X in
patients 3 and 4. The mutation p.C7X
leading to a premature termination
codon in the N terminus of p34 has
not been reported previously (HGMD
Professional 2012.4). Two further unre-
lated patients with comparable clinical
phenotypes were analyzed for AAGAB
mutations; however, none were found.
So far, limited data on the role of p34
are derived from experiments with cell
lines (Giehl et al., 2012; Pohler et al.,
2012). We investigated the consequen-
ces of the AAGAB splice-site mutation
c.870þ1G4A in primary keratinocytes
from patient 1, which were isolated,
cultured (Konig and Bruckner-Tuderman,
1992), and compared with primary
normal human keratinocytes (NK).
Cells were lysed and subjected to
reverse transcripatase–PCR and immu-
noblotting (Pigors et al., 2011). In the
latter experiments, NK immortalized
with the HPV-E6E7 genes (designated
as NK-E6E7) were also included (a gift
from Dr Yannick Gache, Nice; Sprenger
et al., 2010).
Reverse transcripatase–PCR with
primers spanning exon 9 and comple-
mentary DNA from primary patient
keratinocytes and NK demonstrated
comparable single bands (Figure 2a).
The amplicons were cloned into theAccepted article preview online 5 April 2013; published online 16 May 2013
Abbreviations: AAGAB, a- and g-adaptin binding gene; NK, primary normal human keratinocytes;
NK-E6E7, immortalized NK; PPK, palmoplantar keratoderma
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